TY - JOUR AU - Leon-Martinez, Daisy; Bank, Tracy C.; Lundsberg, Lisbet S.; Culhane, Jennifer; Silasi, Michelle; Son, Moeun; Partridge, Caitlin; Reddy, Uma M.; Hoffman, Matthew K.; Merriam, Audrey A. TI - Does Antenatal Progesterone Administration Modify the Risk of Neonatal Intraventricular Hemorrhage? SN - 0735-1631 SN - 1098-8785 PY - 2022 JO - Am J Perinatol JF - American Journal of Perinatology LA - EN IS - EFirst DA - 2022/06/10 ET - 2022/04/18 KW - betamethasone KW - intraventricular hemorrhage KW - magnesium sulfate KW - neonatal brain injury KW - gestational age KW - preterm birth KW - very low birthweight KW - 17-α-hydroxyprogesterone caproate AB - Objective Progesterone administration has been associated with improved neurological outcomes following traumatic brain injury in adults. However, studies examining the effect of progesterone on the risk of neonatal intraventricular hemorrhage (IVH) are inconsistent. We sought to determine if maternal administration of intramuscular 17-α-hydroxyprogesterone caproate (17-OHPC) is associated with decreased rates of IVH in infants born before 32-weeks gestation.Study Design This is a retrospective study of liveborn singleton deliveries between 20- and 32-weeks gestation at two large academic medical centers from January 1, 2012 to August 30, 2020. Data were extracted from hospital electronic medical record data warehouses using standardized definitions and billing and diagnosis codes. We evaluated receipt of 17-OHPC in the antepartum period and diagnosis of IVH (grade I-IV, per Volpe classification) during the neonatal delivery hospitalization encounter. Bivariate and multivariate analyses were performed to examine the association between 17-OHPC and neonatal IVH adjusting for potential confounders. Odds ratio (ORs) and 95% confidence intervals (CIs) were presented.Results Among 749 neonates born between 20- and 32-week gestation, 140 (18.7%) of their mothers had received antenatal 17-OHPC and 148 (19.8%) were diagnosed with IVH after birth. No significant association was observed between maternal 17-OHPC and neonatal IVH in unadjusted (OR 1.14, 95% CI 0.72–1.78) or adjusted analyses (adjusted odds ratio 1.14, 95% CI 0.71–1.84). Independent of exposure to 17-OHPC, as expected, infants born <28-weeks gestation or those with very low birthweight (<1,500 g) were at an increased risk of IVH (OR 2.32, 95% CI 1.55–3.48 and OR 2.19, 95% CI 1.09–4.38, respectively).Conclusion Antenatal maternal 17-OHPC administration was not associated with the risk of neonatal IVH. Further research may be warranted to determine whether timing, route of delivery, and duration of progesterone therapy impact rates of neonatal IVH.Key Points PB - Thieme Medical Publishers, Inc. DO - 10.1055/a-1827-6712 UR - http://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1827-6712 ER -